SCHEMBL692989

SCHEMBL692989

CC(N)(CCCc1ccccc1)C(=O)O

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
GRM2 Q14416 3/20 0.54
GRM3 Q14832 3/20 0.54
POLB P06746 1/20 0.50
SMN1; SMN2 Q16637 2/20 0.48
HDAC3 O15379 2/20 0.48
HDAC4 P56524 2/20 0.48
HDAC1 Q13547 2/20 0.48
HDAC7 Q8WUI4 2/20 0.48
HDAC2 Q92769 2/20 0.48
HDAC10 Q969S8 2/20 0.48
HDAC11 Q96DB2 2/20 0.48
HDAC8 Q9BY41 2/20 0.48
HDAC6 Q9UBN7 2/20 0.48
HDAC9 Q9UKV0 2/20 0.48
HDAC5 Q9UQL6 2/20 0.48
MAPK1 P28482 1/20 0.48
ADRA1A P35348 1/20 0.48
SLC6A3 Q01959 1/20 0.48
ARG1 P05089 1/20 0.47
ARG2 P78540 1/20 0.47

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Hydrochloric Acid SCHEMBL15372829 0.98 GRM2 (0.52) GRM2GRM3POLBSMN1; SMN2HDAC3
SCHEMBL23177172 0.93 LTB4R (0.54) GRM2GRM3POLBSMN1; SMN2HDAC3
SCHEMBL16468979 0.93 LTB4R (0.54) GRM2GRM3POLBSMN1; SMN2HDAC3
SCHEMBL28556411 0.90 SLC13A5 (0.50) GRM2GRM3HDAC1HDAC2LMNA
SCHEMBL27748006 0.89 GRM2 (0.51) GRM2GRM3POLBSMN1; SMN2HDAC3
SCHEMBL202819 0.89 GRM2 (0.51) GRM2GRM3POLBSMN1; SMN2HDAC3
SCHEMBL3616371 0.89 GRM2 (0.51) GRM2GRM3POLBSMN1; SMN2HDAC3
Hydrochloric Acid SCHEMBL31587976 0.87 GRM2 (0.50) GRM2GRM3POLBSMN1; SMN2HDAC3
Hydrochloric Acid SCHEMBL1807415 0.87 GRM2 (0.50) GRM2GRM3POLBSMN1; SMN2HDAC3
SCHEMBL584902 0.81 LTB4R (0.59) GRM2GRM3POLBSMN1; SMN2HDAC3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 32 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20200399311-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE ZYDUS LIFESCIENCES LIMITED (IN) 2020-12-24 US claimed
EP-3609532-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE Cadila Healthcare Limited (IN) 2020-02-19 EP claimed
CN-110536696-A PCSK9 vaccine based on new peptide CADILA HEALTHCARE LTD 2019-12-03 CN claimed
WO-2018189705-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE CADILA HEALTHCARE LIMITED (IN) 2018-10-18 WO claimed
US-8383581-B2 Short-chain peptides as parathyroid hormone (PTH) receptor agonist CADILA HEALTHCARE LIMITED (IN) 2013-02-26 US claimed
WO-2012120532-A2 CYCLIC SHORT CHAIN PEPTIDES CADILA HEALTHCARE LIMITED (IN) 2012-09-13 WO claimed
US-20120108496-A1 SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST CADILA HEALTHCARE LIMITED (IN) 2012-05-03 US claimed
CN-102405229-A Short-chain peptides as parathyroid hormone (PTH) receptor agonists CADILA HEALTHCARE LTD 2012-04-04 CN claimed
EP-2421893-A2 SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST Cadila Healthcare Limited (IN) 2012-02-29 EP claimed
WO-2010128521-A2 SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST CADILA HEALTHCARE LIMITED (IN) 2010-11-11 WO claimed
CN-118256591-A Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-06-28 CN disclosed
CN-110869544-B Cyclic peptide compound having high membrane permeability and library comprising same 中外制药株式会社 2024-03-08 CN disclosed
US-11325945-B2 Peptide based PCSK9 vaccine CADILA HEALTHCARE LIMITED (IN) 2022-05-10 US disclosed
US-20200399311-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE ZYDUS LIFESCIENCES LIMITED (IN) 2020-12-24 US disclosed
CN-110869544-A Cyclic peptide compound having high membrane permeability and library containing same 中外制药株式会社 2020-03-06 CN disclosed
WO-2010128521-A2 SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST CADILA HEALTHCARE LIMITED (IN) 2010-11-11 WO disclosed
US-4808713-A Anthypertensive pyridazo [1,2-a][1,2]diazepines HOFFMAN-LA ROCHE INC. (US) 1989-02-28 US disclosed
US-4772701-A Pyridazo[1,2]pyridazines and pyrazolo[1,2]pyridazines as antihypertensives HOFFMANN-LA ROCHE INC. (US) 1988-09-20 US disclosed
US-4658024-A Pyrazolo [1,2-a][1,2]-diazepines useful as antihypertensives HOFFMANN-LA ROCHE INC. (US) 1987-04-14 US disclosed
US-4512924-A HYPOTENSIVE AGENTS HOFFMANN-LA ROCHE INC. (US) 1985-04-23 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120108496-A1 SHORT-CHAIN PEPTIDES AS PARATHYROID HORMONE (PTH) RECEPTOR AGONIST PTH1R, GIPR, PTMS GRM2 1931/4885GRM3 1460/4885POLB 3831/4885
US-11325945-B2 Peptide based PCSK9 vaccine PCSK9, PCSK7, PCSK6 GRM2 4722/4885GRM3 4238/4885POLB 3143/4885
US-20200399311-A1 NOVEL PEPTIDE BASED PCSK9 VACCINE PCSK9, PCSK7, PCSK6 GRM2 4711/4885GRM3 4280/4885POLB 2744/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.